BioSpace News Archive

Wilmington, Delaware, United States, Transparency Market Research Inc.: Microbiome is a genetic component of various microorganisms such as bacteria, fungi, protozoa, and viruses, which live inside and on the human body.

Wilmington, Delaware, United States, Transparency Market Research Inc.: Transparency Market Research has published a new report titled, ‘Extracorporeal Membrane Oxygenation Machine Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019–2027’.

Wilmington, Delaware, United States, Transparency Market Research Inc.: Huge investments made in biopharmaceutical industry by the key players with the aim to improve their productivity and efficiency.

Wilmington, Delaware, United States, Transparency Market Research Inc.: T-cell therapy includes using genetically engineered T-cells to produce an artificial T-cell receptor for application in immunotherapy.

The spinal imaging market is likely to exhibit exponential growth during the forecast period of 2021-2031 owing to the rising incidences of spinal disorders among the global populace.

Wilmington, Delaware, United States, Transparency Market Research Inc.: Infants or neonatal are generally susceptible to a lot of diseases.

ContraFect Corporation (Nasdaq: CFRX), announces today that the Data Safety Monitoring Board (DSMB) of the DISRUPT (Direct Lysis of Staph aureus Resistant Pathogen Trial) study has completed a pre-specified, interim futility analysis and the DSMB recommended that the trial be stopped because the conditional power of the study was below the pre-specified threshold for futility.

Calithera Biosciences, Inc. (Nasdaq: CALA), announced that updates related to the ongoing clinical programs for sapanisertib (CB-228) and mivavotinib (CB-659) will be presented at the upcoming International Association for Lung Cancer (IASLC) 2022 World Conference on Lung Cancer (WCLC) and the 2022 Pan Pacific Lymphoma Conference, respectively.

Starton Therapeutics Inc., (the “Company”) a clinical stage biotechnology company announced today positive results from high-level data from its Phase 1 study of STAR-LLD, evaluating the pharmacokinetics (PK) and safety of the Company’s continuous delivery lenalidomide program.

Today, the U.S. Food and Drug Administration issued an emergency use authorization (EUA) for the Novavax COVID-19 Vaccine, Adjuvanted for the prevention of COVID-19 caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in individuals 18 years of age and older.